We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Saladax Biomedical Launches Game-Changing Assays at AACC 2018

By LabMedica International staff writers
Posted on 31 Jul 2018
Print article
Image: Saladax Biomedical has launched a new line of tests for psychiatry in Europe (Photo courtesy of Saladax Biomedical).
Image: Saladax Biomedical has launched a new line of tests for psychiatry in Europe (Photo courtesy of Saladax Biomedical).
Saladax Biomedical Inc. (Bethlehem, PA, USA), a diagnostics company providing kits to test drug blood levels for adherence and personalized dose management, announced the launch of its new line of tests for psychiatry in Europe (CE mark) at AACC 2018. Saladax develops novel blood tests that increase the impact of personalized medicine by bringing chemotherapeutic drug monitoring to oncologists and adherence testing to psychiatrists.

Saladax’s MyCare Psychiatry line provides greater clarity on the causes of treatment failure and may help distinguish medication non-response from lack of adherence. The MyCare Psychiatry panel of tests addresses a critical, unmet need for quickly identifying levels of antipsychotic drugs in a patient’s body. A one-hour turnaround time is possible in a STAT mode within a laboratory. Rapid testing has the potential to reduce treatment failures and to positively impact patient management. The MyCare Psychiatry line will launch with tests for clozapine, quetiapine, aripiprazole, risperidone, olanzapine and paliperidone, five of which are currently available for sale in Europe.

“We engineered the MyCare Psychiatry line based on psychiatrists’ needs and extensive research of the market,” said Dr. Salvatore J. Salamone, Founder/CEO. “The result is a game-changer that delivers clinicians access to rapid quantitative blood levels of the psychotherapeutic drugs their patients are on. The MyCare line delivers a fast and accurate result, giving physicians timely information of high medical value, needed to better treat their patients.”

Related Links:
Saladax Biomedical

Gold Member
Troponin T QC
Troponin T Quality Control
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
3-Position Stirrer
ST-200 and SHP-200 Series
New
Automated Immunoassay Analyzer
Phadia 1000

Print article

Channels

Sekisui Diagnostics UK Ltd.